Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:11:45.609Z.
Calculation as of: 2026-10-06T14:11:45.609Z.
Quote observation: 2026-10-06T14:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26b9d76e1867df839f3ea79fd47ae1c5236575fa33f8c6240ddbf9d3395e1dfe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Elicio Therapeutics, Inc.
Market Cap
$36.32M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$36.38M
Operating Cash Flow Yield
N/A
TTM Avg
53.98%
3Y Avg
44.70%
5Y Avg
26.51%
Market Cap
$35.58M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$37.14M
Operating Cash Flow Yield
N/A
TTM Avg
13.07%
3Y Avg
8.54%
5Y Avg
8.65%
Market Cap
$37.81M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.31M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$34.01M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.90M
Operating Cash Flow Yield
1.67%
TTM Avg
21.41%
3Y Avg
13.95%
5Y Avg
10.59%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.32M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.38M | N/A | 53.98% | 44.70% | 26.51% |
| Elutia Inc (ELUT)vs › | $35.82M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.58M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $37.14M | N/A | 13.07% | 8.54% | 8.65% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.81M | N/A | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.31M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.01M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.90M | 1.67% | 21.41% | 13.95% | 10.59% |
| HeartBeam, Inc. (BEAT)vs › | $33.31M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
